Using AI to improve diagnosis and recurrence prediction in thymic tumors
Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors
This study is testing if artificial intelligence can help doctors better diagnose thymic tumors and predict the chances of them coming back for patients with these rare cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1020 (estimated) |
| Sex | All |
| Sponsor | Erasmus Medical Center Academic / other |
| Locations | 1 site (Rotterdam, South Holland) |
| Trial ID | NCT06301945 on ClinicalTrials.gov |
What this trial studies
This study focuses on thymic epithelial tumors, which are rare cancers located in the anterior mediastinum. It aims to develop artificial intelligence models that utilize digital pathology and clinical data to enhance the accuracy of histopathological classification and predict the risk of recurrence for these tumors. By addressing the inconsistencies in tumor subtyping among pathologists, the study seeks to provide a more reliable prognostic tool for patients diagnosed with various subtypes of thymoma and thymic carcinoma. The research will leverage existing databases from multiple centers to train and validate these AI models.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with specific subtypes of thymoma or thymic carcinoma, particularly those with a consensus diagnosis agreement of less than 70%.
Not a fit: Patients with thymic tumors that do not meet the inclusion criteria or those without a documented recurrence outcome within the specified timeframe may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and better predictions of recurrence for patients with thymic epithelial tumors.
How similar studies have performed: Other studies utilizing AI in pathology have shown promise, indicating that this approach could be beneficial, although the specific application to thymic tumors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically: * Thymoma A * Thymoma AB * Thymoma B1 * Thymoma B2 * Thymoma B3 * Thymic Carcinoma Inclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model. Recurrence Criteria: Participants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.
Where this trial is running
Rotterdam, South Holland
- Erasmus MC — Rotterdam, South Holland, Netherlands (Recruiting)
Study contacts
- Study coordinator: Anna Salut Esteve Domínguez
- Email: a.estevedominguez@erasmusmc.nl
- Phone: 0107043491
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.